Citius Oncology (CTOR) Q3 2025 earnings summary

Executive summary

• Preparing for the U.S. commercial launch of LYMPHIR, an FDA-approved immunotherapy for cutaneous T-cell lymphoma, with launch supplies ready, distribution agreements in place, and strong engagement from key opinion leaders.

• Transitioning from a development-stage to a fully integrated commercial organization, with all major launch-enabling activities underway for LYMPHIR's anticipated launch in the second half of 2025.

• Completed a merger and recapitalization in August 2024, resulting in Citius Pharma owning 84.3% of outstanding shares as of July 2025.

• Raised $12.5 million in gross financings during the quarter and an additional $9 million in July 2025 to support pre-launch activities.

Financial highlights

• No revenues reported for the three and nine months ended June 30, 2025 and 2024.

• Net loss for Q3 2025 was $5.4 million, up from $4.8 million in Q3 2024; net loss for the nine months ended June 30, 2025 was $19.76 million, up from $14.34 million year-over-year.

• Operating expenses for Q3 2025 were $4.94 million, up from $4.63 million in Q3 2024; for the nine months ended June 30, 2025, operating expenses were $18.81 million, up from $13.90 million year-over-year.

• Cash and cash equivalents were $112 as of June 30, 2025, with negative working capital of $34.7 million.

• Total assets increased to $91.7 million from $84.4 million as of September 30, 2024.

Outlook and guidance

• LYMPHIR commercial availability planned for Q4 2025, targeting an initial market estimated to exceed $400 million and considered underserved.

• After a July 2025 public offering raising $7.44 million net, management expects sufficient funds to operate through September 2025 but will require additional capital to support operations and complete the LYMPHIR launch beyond that date.

• Actively pursuing additional equity financing and strategic alternatives, with Jefferies LLC retained as exclusive financial advisor.

• Management expects robust market opportunity and competitive positioning due to intellectual property protections.